Beyond debacle and debate: Developing solutions in drug safety

Nature Reviews Drug Discovery

Volumn 8, Issue 10, 2009, Pages 775-779

  Ray, Amrit ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; CARDIOVASCULAR RISK; CLINICAL STUDY; DATA BASE; DRUG APPROVAL; DRUG CONTROL; DRUG LEGISLATION; DRUG MARKETING; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EPIDEMIOLOGICAL DATA; FOOD AND DRUG ADMINISTRATION; INFORMATION PROCESSING; PHARMACOGENOMICS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY;

ANIMALS; DRUG APPROVAL; DRUG INDUSTRY; HUMANS; PHARMACEUTICAL PREPARATIONS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 70349652418     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2988     Document Type: Article

References (24)

1. Reed, S. D., Anstrom, K. J., Seils, D. M., Califf, R. M. & Schulman, K. A. Use of larger versus smaller drug-safety databases before regulatory approval: The trade-offs. Health Affairs. 27, 360-370 (2008).
2. Food and Drug Administration. Endocrinologic and Metabolic Drugs Advisory Committee. FDA web site [online] (2009).
3. Jones, D. Keeping vigilant about drug safety. Nature Rev. Drug Discov. 6, 855-856 (2007).
4. Concato, J., Shah, N., Horwitz, R. I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N. Engl. J. Med. 342, 1887-1892 (2000).
5. Breckenridge, A., Woods, K., Raine, J. Monitoring the safety of licensed medicines. Nature Rev. Drug Discov. 4, 541-543 (2005).
6. The REMS report card: FDA using new tools for one-third of new drugs in first six months. The Pink Sheet (10 Nov 2008).
7. Food and Drug Administration. Questions and answers on the Federal Register notice on drugs and biological products deemed to have REMS. FDA web site [online] (2007).
8. Bate, A., Edwards, I. R. Data mining in spontaneous reports. Basic Clin. Pharmacol. Toxicol. 98, 324-330 (2006).
9. European Medicines Agency. Guideline on the use of statistical signal detection methods in the EudraVigilance data analysis system. EMEA web site [online] (2006).
10. Baciu, A., Stratton, K. & Burke, S. P. (eds). The Future of Drug Safety: Promoting and Protecting the Health of the Public. (National Academy Press, Washington, 2007).
11. European Medicines Agency. Guideline on procedures for the granting of a marketing authorization under exceptional circumstances, pursuant to article 14 (8) of regulation (EC) No 726/2004. EMEA web site [online] (2005).
12. Bouchie, A. Industry reneges on postmarketing trial commitments. Nature Biotech. 21, 718 (2003).
13. Ray, W. A. & Stein, C. M. Reform of drug regulation, beyond an independent drug safety board. N. Engl. J. Med. 354, 194-201 (2006).
14. Gale, E. A. M. Lessons from the glitazones: A story of drug development. Lancet 357, 1870-1875 (2001).
15. Food and Drug Administration. Updated Labeling for Coumadin (Warfarin) (press release). FDA web site [online] (2007).
16. Mallal, S. et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579 (2008).
17. Food and Drug Administration. Information on carbamazepine. FDA web site [online] (2009).
18. Woodcock, J. & Lesko, L. J. Pharmacogenetics - tailoring treatment for the outliers. N. Engl. J. Med. 360, 811-813 (2009).
19. European Medicines Agency. Final report on the pilot joint EMEA/FDA VXDS experience on qualification of nephrotoxicity biomarkers. EMEA web site [online] (2008).
20. Carey, J. Improving the use of drugs through genes. BusinessWeek (Washington) (24 Oct 2008).
21. McKinnon, R. A., Ward, M. B. & Sorich, M. J. A critical analysis of barriers to the clinical implementation of pharmacogenomics. Ther. Clin. Risk Manag. 3, 751-759 (2007).
22. Dow Jones News Service. Accenture and Bristol-Myers Squibb launch pharmaceutical industry's first joint center for pharmacovigilance. Dow Jones Newswire (13 Sept 2007).
23. Balian, J. D. The next generation pharmacovigilance - establishing collaborative partnerships around the globe to enhance efficiency, flexibility, and patient safety. American Pharmaceutical Outsourcing (2008).
24. Shortell, S. M. & Singer, S. J. Improving patient safety by taking the systems seriously. J. Am. Med. Assoc. 299, 445-447 (2008).